Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

321
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
321
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same author

Promoting intestinal regeneration without tumor risk in immune-mediated inflammatory diseases.

Trends in immunology·2026
Same author

Spatiotemporal analysis reveals distinct inflammatory programs underlying chronic colitis.

Immunity·2026
Same author

TNFα signaling in radiation-induced chronic bowel dysfunction suggests therapeutic potential for IBD biologics.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Uncovering Immune Niches in Health and Disease Using Spatial Transcriptomics.

European journal of immunology·2026
Same author

IL-26 from innate lymphoid cells regulates early-life gut epithelial homeostasis by shaping microbiota composition.

The EMBO journal·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Sep 10, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K

Células B en la enfermedad inflamatoria intestinal

Francisca A Castillo1, Bianca C Kern1, Eduardo J Villablanca1

  • 1Division of Immunology and Respiratory Medicine, Department of Medicine, Solna, Karolinska Institutet and University Hospital, Stockholm 17176, Sweden; Center of Molecular Medicine, Stockholm 17176, Sweden.

Immunology letters
|August 22, 2025
PubMed
Resumen

Las células B juegan un papel complejo en las enfermedades inflamatorias intestinales (EII), que van más allá del foco tradicional de células T. Comprender estas diversas funciones de las células B es clave para desarrollar terapias dirigidas para la EII.

Palabras clave:
Los anticuerposCeldas BEnfermedad inflamatoria del intestinoCélulas plasmáticasEstructuras linfoides terciarias

Más Videos Relacionados

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.8K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.8K

Área de la Ciencia:

  • Inmunología
  • Gastroenterología
  • Biología celular

Sus antecedentes:

  • Históricamente se consideraba que las enfermedades inflamatorias intestinales (EII) eran mediadas por células T.
  • La evidencia emergente destaca la participación significativa de las células B en la inflamación intestinal crónica.
  • Las células B normalmente apoyan la tolerancia inmune intestinal y la salud de la mucosa.

Objetivo del estudio:

  • Revisar la comprensión en evolución de las funciones de las células B en la patogénesis de la EII.
  • Enfatizar la necesidad de estrategias terapéuticas selectivas dirigidas a subconjuntos específicos de células B.
  • Explorar el potencial de las inmunoterapias precisas basadas en la dinámica de las células B.

Principales métodos:

  • Revisión de la literatura científica actual sobre la biología de las células B en la EII.
  • Análisis de modelos experimentales que demuestran las funciones de las células B en la inflamación intestinal.
  • Discusión de las observaciones clínicas relativas a las terapias dirigidas a las células B.

Principales resultados:

  • El compartimento de células B está alterado significativamente en la EII, con un aumento de las células plasmáticas y respuestas de anticuerpos alteradas.
  • Los subconjuntos de células B proinflamatorias, como las células Sca1 + PD-L1 + B, surgen durante la EII.
  • Los modelos experimentales muestran funciones perjudiciales y beneficiosas para las células B en la EII.
  • La eficacia limitada de las terapias de agotamiento amplio de células B (por ejemplo, rituximab) sugiere complejidad.

Conclusiones:

  • Las células B tienen un papel multifacético en la EII, actuando como agentes patógenos y reguladores.
  • Se necesitan terapias selectivas para atacar a las células B dañinas y preservar las beneficiosas.
  • La investigación adicional sobre la dinámica espacial, fenotípica y temporal de las células B intestinales es crucial para desarrollar inmunoterapias eficaces para la EII.